Skip to main content

Table 2 Clinicopathological characteristics of patient samples and expression of NCAPG in LUAD

From: NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway

Clinical characteristics

Number of cases (%)

Age (y)

 ≥ 65

160 (54.8)

 < 65

132 (45.2)

Sex

 Male

150 (51.4)

 Female

142 (48.6)

Clinical stage

 I

150 (51.4)

 II

72 (24.7)

 III

51 (17.5)

 IV

19 (6.5)

T classification

 T1

88 (30.1)

 T2

164 (56.2)

 T3

24 (8.2)

 T4

16 (5.5)

N classification

 N0

184 (63.0)

 N1

63 (21.6)

 N2

44 (15.1)

 N3

1 (0.3)

Metastasis

 No

273 (93.5)

 Yes

19 (6.5)

Expression of NCAPG

 Low expression

128 (43.8)

 High expression

164 (56.2)

  1. T for extent of the primary tumor; N for involvement of lymph nodes
  2. T1: Tumor ≤ 3 cm; T2: Tumor > 3 but ≤ 5 cm or tumor involving visceral pleura, main bronchus (not carina), atelectasis to hilum; T3: Tumor > 5 but ≤ 7 cm or invading chest wall, pericardium, phrenic nerve or or separate tumor nodule(s) in the same lobe; T4: Tumor > 7 cm or tumor invading: mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine or tumor nodule(s) in a different ipsilateral lobe
  3. N0: No regional node metastasis; N1: Metastasis in ipsilateral pulmonary or hilar nodes; N2: Metastasis in ipsilateral mediastinal/subcarinal nodes; N3: Metastasis in contralateral mediastinal/hilar, or suprclavicular nodes